Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START phase III trial of Stimuvax in unresectable stage III NSCLC
2006-000579-14Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2006
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tecemotide and cyclophosphamide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival. Started Nov 2006; status: completed.
02
Drugs
tecemotidecyclophosphamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-000579-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000579-14.